Drugs / NRC-2694-A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05283226 | Sep 2022 → Dec 2026 expected | head and neck squamous cell carcinoma | NATCO Pharma Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NRC-2694-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05283226 ↗ |
| Action | Inhibit | “NRC-2694-A is an orally administered small-molecule tyrosine kinase inhibitor.” NCT05283226 ↗ |
| Modality | Small molecule | “NRC-2694-A is an orally administered small-molecule tyrosine kinase inhibitor.” NCT05283226 ↗ |
| Route | Oral | “300 mg orally once daily” NCT05283226 ↗ |